Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Bartosz Chmielowski's publication output changed over time?
ScholarIQpublication output · 2012–2016
Output grew100% over the shown period — from 1 works in 2012 to 2 in 2016.
1
1
1
1
2
20122013201420152016
What are the most-cited papers on Bartosz Chmielowski?
ScholarIQmost cited works
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma Taylor, Lídia Robert, Bartosz Chmielowski, Marko Spasić, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutiérrez, Tristan Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan Emerson, Harlan Robins, Robert H. Pierce, David Elashoff, Caroline Robert, Antoni Ribas
Nature. 20146,675 CitationsOPEN ACCESS
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo, Jesse M. Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu‐Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry, Elizabeth Seja, Shirley H. Lomeli, Xiangju Kong, Mark C. Kelley, Jeffrey A. Sosman, Douglas B. Johnson, Antoni Ribas, Roger S. Lo
Cell. 20163,569 CitationsOPEN ACCESS
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss‐Schaap, Alain P. Algazi, Christine Mateus, Peter D. Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas
New England Journal of Medicine. 20133,407 CitationsOPEN ACCESS
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, Helena Escuin-Ordinas, Willy Hugo, Siwen Hu‐Lieskovan, Davis Y. Torrejon, Gabriel Abril-Rodríguez, Salemiz Sandoval, Lucas Barthly, Justin D. Saco, Blanca Homet Moreno, Riccardo Mezzadra, Bartosz Chmielowski, Kathleen Ruchalski, I. Peter Shintaku, Phillip J. Sanchez, Cristina Puig-Saus, Grace Cherry, Elizabeth Seja, Xiangju Kong, Jia Pang, Beata Berent-Maoz, Begoña Comı́n-Anduix, Thomas G. Graeber, Paul C. Tumeh, Ton N. Schumacher, Roger S. Lo, Antoni Ribas
New England Journal of Medicine. 20163,206 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,672 Citations
Related on ScholarIQ
University of California, Los Angeles
University
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paper
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Paper
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Paper
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Paper
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Paper